Technology evaluation: BAY-50-4798, Bayer.
Bayer is developing an IL-2-selective recombinant cytokine, BAY-50-4798, as a potential adjunct to standard chemotherapy in the treatment of various cancers, and for the potential treatment of HIV infection. BAY-50-4798 is currently undergoing phase II clinical trials.